Gut bacteria may help bladder cancer patients avoid surgery

NCT ID NCT07474064

Not yet recruiting Disease control Sponsor: chenxu Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a probiotic (Clostridium butyricum) to a combination of targeted therapy (Disitamab Vedotin) and immunotherapy (Toripalimab) can help preserve the bladder in people with muscle-invasive bladder cancer who cannot take the chemotherapy drug cisplatin. About 146 participants will receive either the probiotic plus the drug combo or the drug combo alone for one year. The main goal is to see if the probiotic extends the time the bladder remains cancer-free without needing removal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Probiotic (Clostridium butyricum), Disitamab Vedotin, Toripalimab
What this could lead to
If it works, this could offer a way to treat muscle-invasive bladder cancer without removing the bladder, potentially improving quality of life for patients who cannot take standard chemotherapy.
What could go wrong
This is a phase 2 trial with only 146 participants, so results are preliminary. The combination therapy may cause side effects, and the benefit of probiotics is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CANCER (MIBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.